Commerzbank Aktiengesellschaft FI Invests $562,000 in Bioverativ Inc (BIVV)
Commerzbank Aktiengesellschaft FI acquired a new stake in shares of Bioverativ Inc (NASDAQ:BIVV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 9,840 shares of the biotechnology company’s stock, valued at approximately $562,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Bioverativ during the 3rd quarter valued at about $2,560,000. KBC Group NV bought a new position in shares of Bioverativ during the 3rd quarter valued at about $975,000. Pinnacle Associates Ltd. bought a new position in shares of Bioverativ during the 3rd quarter valued at about $217,000. Dimensional Fund Advisors LP bought a new position in shares of Bioverativ during the 3rd quarter valued at about $24,083,000. Finally, Muhlenkamp & Co. Inc. bought a new position in shares of Bioverativ during the 3rd quarter valued at about $636,000. 95.23% of the stock is owned by institutional investors and hedge funds.
Bioverativ Inc (NASDAQ:BIVV) opened at $51.47 on Friday. Bioverativ Inc has a 1-year low of $40.00 and a 1-year high of $64.41.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. The company’s revenue was up 27.2% on a year-over-year basis. analysts forecast that Bioverativ Inc will post 2.45 earnings per share for the current fiscal year.
Several research firms have commented on BIVV. Morgan Stanley reissued an “underweight” rating and set a $47.00 price objective (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Zacks Investment Research raised shares of Bioverativ from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a report on Wednesday, September 20th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $71.00 price target on shares of Bioverativ in a report on Monday, October 23rd. Finally, Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the company a “hold” rating in a report on Monday, November 20th. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $60.93.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.